ERBB2 and neoplasm: Their findings showed that this combination therapy improved anti-tumor immunity when compared to HER2.CAR T-cells therapy alone or HER2.CAR T-cells plus Onc.Ad, as well as the advantages of PD-L1 mini-body created locally, outperform anti-PD-L1 immunoglobulin (Ig)G infused [171].